Auralys Therapeutics is pleased to announce the appointment of Dr. Laila Monroe, M.D., as Chief Medical Officer (CMO), bringing more than two decades of clinical
Auralys Therapeutics presented encouraging preclinical data for its lead candidate, AUR-101, at the prestigious BioTechX Europe 2025 conference, drawing attention from the global scientific and
Auralys Therapeutics, a next-generation biotech company pioneering AI-powered drug discovery, has successfully raised $45 million in Series A funding.The investment round was led by leading
Our mission is to accelerate breakthrough therapies that improve patient outcomes, focusing on diseases with high unmet medical needs. With a world-class team of scientists, drug developers, and industry leaders, Auralys Therapeutics is committed to delivering transformative medicines to the world.
Get the latest updates on scientific breakthroughs, pipeline progress, and company news from Auralys Therapeutics — directly to your inbox.